Cincinnati Wellness Review: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Cincinnati Wellness Review.

October 2025

Mo	Tu	We	Th	Fr	Sa	Su
		1	2	3	4	5
6	7	8	9	10	11	12
13	14	15	16	17	18	19
20	21	22	23	24	25	26
27	28	29	30	31

November 2025

Mo	Tu	We	Th	Fr	Sa	Su
					1	2
3	4	5	6	7	8	9
10	11	12	13	14	15	16
17	18	19	20	21	22	23
24	25	26	27	28	29	30

December 2025

Mo	Tu	We	Th	Fr	Sa	Su
1	2	3	4	5	6	7
8	9	10	11	12	13	14
15	16	17	18	19	20	21
22	23	24	25	26	27	28
29	30	31

Press releases published on November 7, 2025

November 7, 2025

Elevate You Wellness & Aesthetics Partners with GetHairMD™ to Bring Advanced Hair Restoration Services to Dayton

EIN Presswire

November 7, 2025

Revolutionary Autism Training System Launches: Patent Filed for Modular Life & Job Skills Program

EIN Presswire

November 7, 2025

Vera Therapeutics Submits Biologics License Application to U.S. FDA through Accelerated Approval Program for Atacicept for the Treatment of Adults with IgA Nephropathy

GlobeNewswire

November 7, 2025

Data for Lorundrostat in Chronic Kidney Disease and Hypertension Presented at American Society of Nephrology (ASN) Kidney Week 2025

GlobeNewswire

November 7, 2025

AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets Demonstrate Positive Real-world Impact, with Patients Reporting Improvement in Involuntary Movements and Activities of Daily Living

GlobeNewswire

November 7, 2025

Evaxion presents new immune data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01

GlobeNewswire

November 7, 2025

Replimune Presents Late-Breaking Abstract and Additional Posters on RP1 at 40th Annual Meeting of the Society for the Immunotherapy of Cancer (SITC 2025)

GlobeNewswire

November 7, 2025

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

November 7, 2025

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

November 7, 2025

Cellectis Reports Third Quarter 2025 Financial Results and Provides Business Update

GlobeNewswire

November 7, 2025

Cannabix Technologies announces Non-Brokered LIFE Private Placement

GlobeNewswire

November 7, 2025

Spyre Therapeutics Announces Grants of Inducement Awards

GlobeNewswire

November 7, 2025

Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

November 7, 2025

Surrozen Reports Third Quarter 2025 Financial Results and Provides Business Update

GlobeNewswire

November 7, 2025

Nanox to Report Third Quarter 2025 Financial Results on November 20, 2025

GlobeNewswire

November 7, 2025

Arcadia Biosciences (RKDA) Announces Third Quarter 2025 Financial Results and Business Highlights

GlobeNewswire

November 7, 2025

BillionToOne Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

GlobeNewswire

November 7, 2025

InflaRx to Announce Topline Data from Phase 2a Clinical Trial of INF904 in Hidradenitis Suppurativa and Chronic Spontaneous Urticaria

GlobeNewswire

November 7, 2025

Real-World Evidence Studies of XPHOZAH® (tenapanor) Demonstrate Patient Satisfaction and Reduction in Serum Phosphate with XPHOZAH in Data Presented at ASN Kidney Week

GlobeNewswire

November 7, 2025

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire